NCT02807103View on ClinicalTrials.gov

Rituximab in Eosinophilic Granulomatosis With Polyangiitis

PHASE3CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

December 5, 2016

Primary Completion Date

October 21, 2020

Study Completion Date

October 21, 2020

Conditions
Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Interventions
DRUG

Rituximab

1 g intravenous pulse at day1 and day15

DRUG

Placebo-rituximab

intravenous pulses at day1 and day15

DRUG

Cyclophosphamide

intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.

DRUG

Placebo-cyclophosphamide

intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.

Trial Locations (1)

75014

Hôpital Cochin, Paris

All Listed Sponsors
collaborator

French Vasculitis Study Group

OTHER

lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02807103 - Rituximab in Eosinophilic Granulomatosis With Polyangiitis | Biotech Hunter | Biotech Hunter